PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Frequently asked questions
What sector does PolyPeptide Group AG (PPGN) operate in?
PolyPeptide Group AG belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is PolyPeptide Group AG (PPGN) current stock price?
As of the latest data, PolyPeptide Group AG stock price is CHF 44.00, with a previous close of CHF 43.95. PolyPeptide Group AG gained CHF 0.05 in the last trading session, representing a 0.11% increase.
What is PolyPeptide Group AG (PPGN) current market capitalization?
PolyPeptide Group AG market cap is approximately 1.45 billion.
What is PolyPeptide Group AG (PPGN) Earnings Per Share (EPS)?
The trailing EPS is -CHF 0.60, and the forward EPS is CHF 1.55.
Does PolyPeptide Group AG (PPGN) pay dividends?
No. PolyPeptide Group AG does not pay a dividend.
When is PolyPeptide Group AG (PPGN) next earnings report?
PolyPeptide Group AG is expected to release its next earnings report on June 30, 2026.
What is PolyPeptide Group AG (PPGN) beta (volatility) score?
PolyPeptide Group AG has a beta of 1.002, meaning its volatility is roughly in line with the market.
